Point72 Asset Management and affiliates report beneficial ownership of 4,085,017 shares of Pliant Therapeutics, Inc. (PLRX), representing 6.7% of the outstanding common stock as of the close of business on September 3, 2025. The filing is a Schedule 13G showing that Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen share voting and dispositive power over these shares and that the shares are held by an investment fund managed by Point72 Asset Management (Point72 Associates).
The statement clarifies that none of the reporting persons own shares directly and that Point72 Associates has the right to receive dividends or sale proceeds for more than 5% of the class. A Joint Filing Agreement (Exhibit 99.1) is referenced.
Positive
Disclosure of material ownership: Point72 reports a clear beneficial ownership stake of 4,085,017 shares representing 6.7% of PLRX.
Joint Filing Agreement referenced: The filing cites an Exhibit 99.1 joint filing agreement, clarifying coordination among reporting persons.
Certification of passive intent: The filing includes a certification that the shares were not acquired to change or influence control of the issuer.
Negative
None.
Insights
TL;DR: Point72 holds a meaningful 6.7% stake in PLRX via managed funds, signaling notable institutional ownership without intent to influence control.
The Schedule 13G discloses a 6.7% beneficial ownership position by Point72-related reporting persons, consistent with passive/investment-adviser reporting under Rule 13d-1. Reported shared voting and dispositive power of 4,085,017 shares indicates centralized portfolio management via Point72 Associates. The filing date and specified ownership as of September 3, 2025, provide a clear snapshot of institutional exposure but include no transactions, timing of purchases, or economic terms.
TL;DR: A formal joint 13G filing documents control relationships and confirms that the position is held for investment, not for changing issuer control.
The document includes a Joint Filing Agreement among Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen and contains the certification that the securities were not acquired to change or influence control of the issuer. The filing identifies shared voting/dispositive power and notes that Point72 Associates can direct dividends or sale proceeds exceeding 5% of the class—an important disclosure for governance transparency.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
PLIANT THERAPEUTICS, INC.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
729139105
(CUSIP Number)
08/27/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
729139105
1
Names of Reporting Persons
Point72 Asset Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,085,017.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,085,017.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,085,017.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.7 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP No.
729139105
1
Names of Reporting Persons
Point72 Capital Advisors, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,085,017.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,085,017.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,085,017.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.7 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP No.
729139105
1
Names of Reporting Persons
Steven A. Cohen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,085,017.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,085,017.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,085,017.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.7 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
PLIANT THERAPEUTICS, INC.
(b)
Address of issuer's principal executive offices:
331 Oyster Point Boulevard, South San Francisco, CA 94080
Item 2.
(a)
Name of person filing:
This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.0001 per share ("Shares"), of Pliant Therapeutics, Inc. held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the Shares held by Point72 Associates; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.
Each of Cubist Systematic Strategies, LLC, Point72 Asia (Singapore) Pte. Ltd. and Point72 (DIFC) Limited are advisors under common control with Point72 Asset Management, and each acts as a sub-advisor with respect to a portion of the Shares reported herein.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
(c)
Citizenship:
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
729139105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 3, 2025.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.
(b)
Percent of class:
6.7%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 3, 2025.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 3, 2025.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 3, 2025.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 3, 2025.
Item 5.
Ownership of 5 Percent or Less of a Class.
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
How many Pliant Therapeutics (PLRX) shares does Point72 beneficially own?
Point72 beneficially owns 4,085,017 shares, representing 6.7% of PLRX as of the close of business on September 3, 2025.
Who filed the Schedule 13G for PLRX on behalf of Point72?
The statement is filed by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen under a joint filing agreement.
Does the filing state whether Point72 intends to influence control of Pliant Therapeutics?
Yes. The filing includes a certification that the securities were not acquired and are not held to change or influence control of the issuer.
Where are the voting and dispositive powers held for the reported shares?
The reported shares show 0 sole voting or dispositive power and 4,085,017 shares of shared voting and dispositive power among the reporting persons.
Which entity holds the right to receive dividends or sale proceeds for the shares?
Point72 Associates, LLC (an investment fund managed by Point72 Asset Management) has the right to receive dividends or proceeds and holds the reported shares.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
You have made too many password recovery requests. Please try again tomorrow.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
